DeepMed Research

VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Cabotegravir Tablets
Drug: Cabotegravir Injectable Suspension (CAB LA)
Drug: BIKTARVY Tablets (BIK)
Drug: Rilpivirine Tablets
Drug: Rilpivirine Injectable Suspension (RPV LA)

First Posted Date: 2020-09-09

Last Posted Date: 2024-06-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 687

Registration Number: NCT04542070

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254 Oral tablet
Drug: [14C]-GSK3640254 intravenous infusion
Drug: [14C]-GSK3640254 powder

First Posted Date: 2020-08-11

Last Posted Date: 2022-01-31

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 5

Registration Number: NCT04507321

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Phase 2

Terminated

Conditions: HIV Infections

Interventions: Drug: GSK3640254
Drug: ABC/3TC
Drug: FTC/TAF
Drug: Dolutegravir
Drug: Placebo

First Posted Date: 2020-07-30

Last Posted Date: 2024-06-26

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 161

Registration Number: NCT04493216

Locations: 🇨🇭
GSK Investigational Site, Zuerich, Switzerland

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3739937 (PIB)
Drug: Placebo
Drug: GSK3739937 (Tablet)

First Posted Date: 2020-07-30

Last Posted Date: 2023-08-23

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 91

Registration Number: NCT04493684

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Cabotegravir sodium (Oral Lead In)
Drug: Cabotegravir 400 mg/mL
Drug: Cabotegravir 200 mg/mL
Drug: Recombinant human hyaluronidase PH20 (rHuPH20)
Drug: Topical non-steroidal anti-inflammatory drug
Drug: Topical steroid
Drug: Placebo creams/gels

First Posted Date: 2020-07-23

Last Posted Date: 2023-12-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 138

Registration Number: NCT04484337

Locations: 🇳🇿
GSK Investigational Site, Auckland, New Zealand

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254 200 mg
Drug: Caffeine 200 mg
Drug: Metoprolol 100 mg
Drug: Montelukast 10 mg
Drug: Flurbiprofen 100 mg
Drug: Omeprazole 40 mg
Drug: Midazolam 5 mg (2.5 mL)
Drug: Digoxin 0.25 mg
Drug: Pravastatin 40 mg

First Posted Date: 2020-06-11

Last Posted Date: 2024-01-05

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 20

Registration Number: NCT04425902

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: CAB OLI
Other: Continuous Quality Improvement (CQI) calls
Drug: CAB LA
Drug: RPV OLI
Drug: RPV LA

First Posted Date: 2020-05-22

Last Posted Date: 2024-04-05

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 437

Registration Number: NCT04399551

Locations: 🇪🇸
GSK Investigational Site, Zaragoza, Spain

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Cabotegravir Tablets
Drug: Rilpivirine Tablets
Drug: Cabotegravir extended release suspension for injection (long-acting)
Drug: Rilpivirine extended release suspension for injection (long-acting)

First Posted Date: 2020-05-01

Last Posted Date: 2024-04-22

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 15

Registration Number: NCT04371380

Locations: 🇺🇸
GSK Investigational Site, Glendale, California, United States

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: GSK3640254 Tablet
Drug: GSK3640254 Capsule

First Posted Date: 2020-02-10

Last Posted Date: 2021-03-03

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 39

Registration Number: NCT04263142

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)

Conditions: HIV Infections

First Posted Date: 2020-01-18

Last Posted Date: 2025-05-13

Lead Sponsor: ViiV Healthcare

Registration Number: NCT04233047

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy